With regard to the assessment of VEGFR2 expression in the molecular late phase, on day 7 significantly lower SI8min and SI10min values were observed in the therapy group compared to the control group at follow-up, reflecting a significantly lower number of MB bound to VEGFR2 on the tumor endothelial surface in tumors following regorafenib therapy. The gene discussed is KDR; the disease is neoplasm.